Search | Clinical Trials Finder

Conditions: Alcohol Drinking, Problem Drinking
Interventions: Alcohol Cue Reactivity Personalized Feedback Intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 24 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Drug Resistant Epilepsy, Refractory Epilepsy
Interventions: Participants are not assigned an intervention as part of the study.; Other
Lead sponsor: NeuroOne Medical Technologies Corporation; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Miami, Florida • Livingston, New Jersey • New Brunswick, New Jersey

Conditions: Chronic Pain, Mental Health Disorders, Behavioral Health Challenges, Ecological Momentary Assessment Best Practices
Interventions: Digital Biopsychosocial Conversational Data Collection Software, Standard Digital Questionnaire Data Collection; Other
Lead sponsor: AugMend Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Sensorineural Hearing Loss, Tinnitus, SNHL, Inner Ear Hearing Loss
Interventions: ACEMg; Dietary Supplement
Lead sponsor: Keep Hearing, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Cancer, Advanced Cancer
Interventions: Social Determinants of Health and toxicity questionnaires; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 10,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (BAY 94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Multiple Locations, New Jersey

Conditions: Amyotrophic Lateral Sclerosis, Brain Stem Stroke, Cerebral Palsy, Traumatic Brain Injury, Speech Disorders
Interventions: Speech generating device (SGD) evaluation including BCI access, Training and treatment; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Carnegie, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Planet T1D; Behavioral
Lead sponsor: 3-C Institute for Social Development; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions: Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care; Other · Behavioral · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
Interventions: Cerene; Device
Lead sponsor: Channel Medsystems; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: West Orange, New Jersey • Cincinnati, Ohio

Conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions: Ziconotide; Drug
Lead sponsor: Christian Hospital Northeast Northwest; Other
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza, Human, COVID-19
Interventions: Comirnaty, Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,442,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions: Not listed
Lead sponsor: MPN Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Weeks and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 17,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Arthritis, Rheumatoid
Interventions: Abatacept; Drug
Lead sponsor: Arthritis Northwest PLLC; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Hypertrophic Cardiomyopathy
Interventions: Viz HCM; Device
Lead sponsor: Viz.ai, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Evanston, Illinois • Philadelphia, Pennsylvania

Conditions: Memory, Delayed
Interventions: Deep Brain Stimulation, Memory and spatial navigation tasks, Physiological Signals, Questionnaires and Assessments; Device · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: CardioMEMS HF System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Central Nervous System Infection
Interventions: Delve Detect CSF mNGS Test, Real-World Data; Diagnostic Test · Other
Lead sponsor: Delve Bio, Inc.; Industry
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 2 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Exposure therapy; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: San Diego, California • Belmont, Massachusetts

Conditions: Dietary Intakes, Physical Activity, Child Care, Early Education, Children Aged 3-5 Years, Toddlers
Interventions: Boston Healthy Child Care Initiative; Other
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 2 Years to 5 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Testing Brief Personalized Feedback Integrating EMA Alcohol Cue Information

Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

Evaluating the Acceptability, Feasibility and Usability of Various Conversational Data Collection Software

ACEMg Hearing Preservation, Tinnitus and Hyperacusis Relief

Evaluating Disparities in Precision Oncology

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Real World Testing of a Brain-Computer Interface

A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

Prediction and Prevention of Postoperative Mortality and Morbidity

A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Real-world Clinical Efficacy of Abatacept in the T3 Data Registry

VIZ ACCESS HCM - Multi-Site Registry

Neural Correlates of Real World Spatial Navigation in Humans

CardioMEMS HF System Real-World Evidence Post-Approval Study

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

Mechanisms of Exposure Therapy for OCD

Implementing Modified Practices to Leverage Evidence for Movement, Engagement, and Nutrition Topics in Early Childcare and Education